Clinicopathological characteristics of Xp11.2 translocation/TFE3 gene fusion-associated renal cell carcinoma

瞿元元,张海梁,叶定伟,戴波,朱耀,顾成元,顾伟杰,常坤,王弘恺

DOI: https://doi.org/10.3760/cma.j.issn.1000-6702.2014.09.001

2014-01-01

Abstract:Objective To investigate the clinical and pathological characteristics of Xp11.2 translocation/TFE3 gene fusion-associated renal cell carcinoma.Methods Between Jan 2009 and Jul 2013,37 patients with Xp1 1.2 translocation/TFE3 gene fusion-associated renal cell carcinoma,consisting of 17 males and 20 females,were treated in our institution.The median age was 22 years old,which ranged from 3 to 73 years old.The clinical symptoms included painless gross hematuria and (or) flank pain in 18 cases,abdominal mass in 3 cases and no significant clinical presentation in 16 cases.3 patients were diagnosed with distant metastasis,including cervical metastasis in 1 case and hepatic metastasis in 2 cases.All patients were treated with surgical treatment,of which 29 patients received radical nephrectomy,4 patients received nephron sparing surgery and 4 patients received palliative nephrectomy.Of the 37 patients,10 cases received adjuvant sorafenib or sunitinib target therapy after surgery.Results The final pathological diagnosis was Xp11.2 translocation/TFE3 gene fusion-associated renal cell carcinoma in all patients.The maximum diameter of tumor ranged from 1 to 15 cm (mean 6.5 cm).The pathological examination showed the tumor cells contained eosinophilic cytoplasm with psammoma bodies in renal interstitial tissue.Immunohistochemical examination showed that all patients were positive for TFE3,30 patients were positive for CD10,28 patients were positive for P504S and variably positive for CK7,CK8,Vimentin and EMA.The mean follow-up duration was 22 months (range,1-55 months).33 patients survive and 4 patients died due to the tumor recurrence and systemic metastasis.As being treated with adjuvant target therapy,the patient with cervical metastasis has maintained stable,and another 2 patients with hepatic metastases have achieved partial remission.Conclusions Xp11.2 translocation/TFE3 gene fusion-associated renal cell carcinoma is a newly defined rare entity with a high predominance of young patients.The diagnosis mainly depends on patient's age,histopathological characteristics,and TFE3-positive immune markers.Patients with metastatic Xp1 1.2 translocation/TFE3 gene fusion-associated renal cell carcinoma could benefit from the target therapy.